Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14ARF tumor suppressor genes

Journal of Virology

Volumn 76, Issue 24, 2002, Pages 12483-12490

  Edwards, Sara J ^a   Dix, Brett R ^a,c   Myers, Colleen J ^a   Dobson Le, Deirdre ^a   Huschtscha, Lily ^b   Hibma, Merilyn ^a   Royds, Janice ^a   Braithwaite, Antony W ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ONYX 015; PROTEIN P14; PROTEIN P53;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIVISION; CELL STRAIN HEPG2; CELL TYPE; CONTROLLED STUDY; DRUG EFFICACY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

ADENOVIRIDAE; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0036891811     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.24.12483-12490.2002     Document Type: Article

References (46)

1. Babiss, L. E., H. S. Ginsberg, and J. E. Darnell, Jr. 1985. Adenovirus EIB proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell. Biol. 5:2552-2558.
2. Barker, D. D., and A. J. Berk. 1987. Adenovirus proteins from both E1b reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107-121.
3. ARF links the tumour suppressors Rb and p53. Nature 395:124-125.
4. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 274:373-376.
5. Braithwaite, A. W., G. E. Blair, C. C. Nelson, J. McGovern, and A. J. Bellett. 1991. Adenovirus E1b58kD antigen binds to p53 during infection of rodent cells: Evidence for an N-terminal binding site on p53. Oncogene 6:781-787.
6. Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:2438-2451.
7. Chiou, S. K., and E. White. 1997. p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J. Virol. 71:3515-3525.
8. Dix, B. R., S. J. Edwards, and A. W. Braithwaite. 2001. Does the antitumor virus ONYX-015/d/1520 selectively target cells defective in the p53 pathway? J. Virol. 75:5443-5447.
9. Dix, B. R., S. J. O'Carroll, C. J. Myers, S. J. Edwards, and A. W. Braithwaite. 2000. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res. 60:2666-2672.
10. Gallimore, P. H., and A. S. Turnell. 2001. Adenovirus E1A: Remodelling the host cell, a life or death experience. Oncogene 20:7824-7835.
11. Geoerger, B., J. Grill, P. Opolon, J. Morizet, G. Aubert, M. J. Terrier-Lacombe, B. Bressac De-Paillerets, M. Barrois, J. Feunteun, D. H. Kirn, and G. Vassal. 2002. Oncolytic activity of the E1B-55kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62:764-772.
12. Goodrum, F. D., and D. A. Ornelles. 1998. p53 status does not determine outcome of E1b 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:9479-9490.
13. Grand, R. J., M. L. Grant, and P. H. Gallimore. 1994. Enhanced expression of p53 in human cells infected with mutant adenoviruses. Virology 203:229-240.
14. Grand, R. J., D. Owen, S. M. Rookes, and P. H. Gallimore. 1996. Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins. Virology 218:23-34.
15. Hall, A. R., B. R. Dix, S. J. O'Carroll, and A. W. Braithwaite. 1998. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. 4:1068-1072.
16. Heise, C., M. Lemmon, and D. Kirn. 2000. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res. 6:4908-4914.
17. Heise, C., A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, and D. H. Kirn. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:639-645.
18. INK4a. Biochem. Biophys. Res. Commun. 231:743-750.
19. Hollstein, M., D. Sidransky, B. Vogelstein, and C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
20. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 58:3508-3512.
21. Lowe, S., and H. Ruley. 1993. Stabilization of the p53 tumour suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7:535-545.
22. Masuda, H., C. Miller, H. P. Koeffler, H. Battifora, and M. J. Cline. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA 84:7716-7719.
23. Momand, J., G. Zambetti, D. Olson, D. George, and A. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
24. Nemunaitis, J., I. Ganly, F. Khuri, J. Arseneau, J. Kuhn, T. McCarty, S. Landers, P. Maples, L. Romel, B. Randlev, T. Reid, S. Kaye, and D. Kirn. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 60:6359-6366.
25. Nevins, J. R. 1994. Cell cycle targets of the DNA tumor viruses. Curr. Opin. Genet. Dev. 4:130-134.
26. O'Carroll, S. J., A. R. Hall, C. J. Myers, A. W. Braithwaite, and B. R. Dix. 2000. Quantifying adenoviral titers by spectrophotometry. BioTechniques 28:408-410.
27. Phillips, A. C., S. Bates, K. M. Ryan, K. Helin, and K. H. Vousden. 1997. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 11:1853-1863.
28. Pilder, S., M. Moore, J. Logan, and T. Shenk. 1986. The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol. Cell. Biochem. 6:470-476.
29. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
30. Querido, E., J. G. Teodoro, and P. E. Branton. 1997. Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J. Virol. 71:3526-3533.
31. Ridgway, P. J., A. R. Hall, C. J. Myers, and A. W. Braithwaite. 1997. p53/E1b58kDa complex regulates adenovirus replication. Virology 237:404-413.
32. ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6:1128-1133.
33. INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol. Cell. Biol. 15:4745-4753.
34. Rothmann, T., A. Hengstermann, N. J. Whitaker, M. Scheffner, and H. zur Hausen. 1998. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:9470-9478.
35. Slichenmyer, W. J., W. G. Nelson, R. J. Slebos, and M. B. Kastan. 1993. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:4164-4168.
36. Smith, R., R. Heubner, and W. Rowe. 1956. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer Res. 9:1211-1218.
37. Steegenga, W. T., N. Riteco, A. G. Jochemsen, F. J. Fallaux, and J. L. Bos. 1998. The large E1B protein together with the E4ORF6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16:349-357.
38. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
39. Turnell, A. S., R. J. Grand, and P. H. Gallimore. 1999. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73:2074-2083.
40. Turnell, A. S., R. J. Grand, C. Gorbea, X. Zhang, W. Wang, J. S. Mymryk, and P. H. Gallimore. 2000. Regulation of the 26S proteasome by adenovirus E1A. EMBO J. 19:4759-4773.
41. INK4 and telomerase in immortalisation of human cells. Oncogene 11:971-976.
42. Whyte, P., K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, and E. Harlow. 1988. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334:124-129.
43. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357:82-85.
44. Yew, P. R., X. Liu, and A. J. Berk. 1994. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 8:190-202.
45. Zantema, A., P. I. Schrier, A. Davis-Olivier, T. van Laar, R. T. Vaessen, and A. J. van der Eb. 1985. Adenovirus serotype determines association and localization of the large E1B tumor antigen with cellular tumor antigen p53 in transformed cells. Mol. Cell. Biol. 5:3084-3091.
46. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.